NA
JAZZ icon

Navellier & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Navellier & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,272
Closed -$863K – 367
2014
Q4 		$863K Sell
5,272
-80
-1% -$13.3K 0.04% 119
2014
Q3 		$859K Sell
5,352
-4,073
-43% -$626K 0.04% 116
2014
Q2 		$1.39M Sell
9,425
-19,684
-68% -$2.73M 0.06% 74
2014
Q1 		$4.04M Buy
29,109
+22,081
+314% +$3.32M 0.19% 42
2013
Q4 		$889K Buy
+7,028
New +$727K 0.04% 114

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Navellier & Associates's JAZZ Position: Q1 2015 in Review

Navellier & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2015, closing a stake of 5,272 shares — an estimated $863K sold.

Navellier & Associates first reported a position in JAZZ in Q4 2013 and held it in 5 quarters. The position peaked at $4.04M in Q1 2014. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

  • Navellier & Associates reported no remaining Jazz Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Navellier & Associates sold 5,272 Jazz Pharmaceuticals shares in Q1 2015, an estimated $863K.
  • Navellier & Associates first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Navellier & Associates's Jazz Pharmaceuticals position peaked at $4.04M in Q1 2014.
  • 354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on Navellier & Associates's 13F filing for Q1 2015, filed 18 May 2015.